Role of IL-32 Gamma on Bone Metabolism in Autoimmune Arthritis

키워드

참고문헌 (60)

1. Jung SM, "Cytokine-mediated bone destruction in rheumatoid arthritis", J Immunol Res, 2014, pp.263625~ (2014)
2. Lories R, "The balance of tissue repair and remodeling in chronic arthritis", Nat Rev Rheumatol, 7, pp.700~707 (2011)[DOI]
3. Khawar B, "A panoramic spectrum of complex interplay between the immune system and IL-32 during pathogenesis of various systemic infections and inflammation", Eur J Med Res, 20, pp.7~ (2015)[DOI]
4. Dinarello CA, "IL-32, a novel cytokine with a possible role in disease", Ann Rheum Dis, 65(Suppl 3), pp.iii61~iii64 (2006)
5. Khawar MB, "Il-32: a novel pluripotent inflammatory interleukin, towards gastric inflammation, gastric cancer, and chronic rhino sinusitis", Mediators Inflamm, 2016, pp.8413768~ (2016)
6. 김수현, "Interleukin-32 in Inflammatory Autoimmune Diseases", Immune Network, 14(3), pp.123~127 (2014), 대한면역학회
7. Xu WD, "IL-32 with potential insights into rheumatoid arthritis", Clin Immunol, 147, pp.89~94 (2013)[DOI]
8. Kim SH, "Interleukin-32: a cytokine and inducer of <TEX>$TNF{\alpha}$<", TEX>, 2005, pp.22, 131~142
9. Calabrese F, "IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease", Am J Respir Crit Care Med, 178, pp.894~901 (2008)[DOI]
10. Shoda H, "Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases", Arthritis Res Ther, 8, pp.R166~ (2006)[DOI]
11. Zhou Y, "Important role of the IL-32 inflammatory network in the host response against viral infection", Viruses, 7, pp.3116~3129 (2015)[DOI]
12. 김선종, "Interleukin-32γ Transgenic Mice Resist LPS-Mediated Septic Shock", Journal of Microbiology and Biotechnology, 24(8), pp.1133~1142 (2014), 한국미생물·생명공학회[DOI]
13. 서은희, "Detection of Expressed IL-32 in Human Stomach Cancer Using ELISA and Immunostaining", Journal of Microbiology and Biotechnology, 18(9), pp.1606~1612 (2008), 한국미생물·생명공학회
14. Sorrentino C, "Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype", Am J Respir Crit Care Med, 180, pp.769~779 (2009)[DOI]
15. Nishida A, "Interleukin-32 expression in the pancreas", J Biol Chem, 284, pp.17868~17876 (2009)[DOI]
16. Kang YH, "Dysregulation of overexpressed IL-<TEX>$32{\alpha}$<", TEX> in hepatocellular carcinoma suppresses cell growth and induces apoptosis through inactivation of <TEX>$NF-{\kappa}B$<, Cancer Lett, pp.2012, 318[DOI]
17. Kang JW, "Interaction network mapping among IL-32 isoforms", Biochimie, 101, pp.248~251 (2014)[DOI]
18. Choi JD, "Identification of the most active interleukin-32 isoform", Immunology, 126, pp.535~542 (2009)[DOI]
19. El-Far M, "Proinflammatory isoforms of IL-32 as novel and robust biomarkers for control failure in HIV-infected slow progressors", Sci Rep, 6, pp.22902~ (2016)[DOI]
20. Heinhuis B, "Interleukin-32: a predominantly intracellular proinflammatory mediator that controls cell activation and cell death", Cytokine, 60, pp.321~327 (2012)[DOI]
21. Lee EJ, "Interleukin-32 gamma stimulates bone formation by increasing mir-29a in osteoblastic cells and prevents the development of osteoporosis", Sci Rep, 7, pp.40240~ (2017)[DOI]
22. Lee EJ, "High level of interleukin-32 gamma in the joint of ankylosing spondylitis is associated with osteoblast differentiation", Arthritis Res Ther, 17, pp.350~ (2015)[DOI]
23. Kim YG, "Effect of interleukin-<TEX>$32{\gamma}$<", TEX> on differentiation of osteoclasts from CD14+ monocytes, 2010, pp.62, 515~523
24. Bae S, "Elevated interleukin-32 expression in granulomatosis with polyangiitis", Rheumatology (Oxford), 51, pp.1979~1988 (2012)[DOI]
25. Gasiuniene E, "Levels of il-32 in serum, induced sputum supernatant, and bronchial lavage fluid of patients with chronic obstructive pulmonary disease", COPD, 13, pp.569~575 (2016)[DOI]
26. Novick D, "Proteinase 3 is an IL-32 binding protein", Proc Natl Acad Sci U S A, 103, pp.3316~3321 (2006)[DOI]
27. Koutsokera A, "Pulmonary biomarkers in COPD exacerbations: a systematic review", Respir Res, 14, pp.111~ (2013)[DOI]
28. Barnes PJ, "Immunology of asthma and chronic obstructive pulmonary disease", Nat Rev Immunol, 8, pp.183~192 (2008)[DOI]
29. Damen MS, "Interleukin-32 in chronic inflammatory conditions is associated with a higher risk of cardiovascular diseases", Atherosclerosis, 264, pp.83~91 (2017)[DOI]
30. Netea MG, "IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-<TEX>$1{\beta}$<", TEX> and IL-6 production through a caspase 1-dependent mechanism, 2005, pp.102, 16309~16314
31. Peyrin-Biroulet L, "NODs in defence: from vulnerable antimicrobial peptides to chronic inflammation", Trends Microbiol, 14, pp.432~438 (2006)[DOI]
32. Imaeda H, "A new isoform of interleukin-32 suppresses IL-8 mRNA expression in the intestinal epithelial cell line HT-29", Mol Med Rep, 4, pp.483~487 (2011)
33. Choi J, "Paradoxical effects of constitutive human IL-<TEX>$32{\gamma}$<", TEX> in transgenic mice during experimental colitis, 2010, pp.107, 21082~21086
34. Kang JW, "A proinflammatory cytokine interleukin-<TEX>$32{\beta}$<", TEX> promotes the production of an anti-inflammatory cytokine interleukin-10, 2009, pp.128, e532~e540
35. Zhang M, "Serum levels of cytokines in systemic lupus erythematosus: association study in a Chinese population", Z Rheumatol, 73, pp.277~280 (2014)[DOI]
36. Inoue M, "Three cases of lupus nephritis patients with serum interleukin-<TEX>$32{\gamma}$<", TEX> detection, 2014, pp.23, 1187~1191
37. Meyer N, "IL-32 is expressed by human primary keratinocytes and modulates keratinocyte apoptosis in atopic dermatitis", J Allergy Clin Immunol, 125, pp.858~865 (2010)[DOI]
38. Heinhuis B, "Inflammation-dependent secretion and splicing of IL-<TEX>$32{\gamma}$<", TEX> in rheumatoid arthritis, 2011, pp.108, 4962~4967
39. Joosten LA, "IL-32, a proinflammatory cytokine in rheumatoid arthritis", Proc Natl Acad Sci U S A, 103, pp.3298~3303 (2006)[DOI]
40. Nakayama M, "Enhanced susceptibility to lipopolysaccharide-induced arthritis and endotoxin shock in interleukin-32 alpha transgenic mice through induction of tumor necrosis factor alpha", Arthritis Res Ther, 14, pp.R120~ (2012)[DOI]
41. 이은진, "Interleukin-32 Gamma as a New Face in Inflammatory Bone Diseases", 대한류마티스학회지, 24(1), pp.14~20 (2017), 대한류마티스학회[DOI]
42. McInnes IB, "Cytokines in the pathogenesis of rheumatoid arthritis", Nat Rev Immunol, 7, pp.429~442 (2007)[DOI]
43. Takayanagi H, "Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems", Nat Rev Immunol, 7, pp.292~304 (2007)[DOI]
44. Gravallese EM, "Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor", Arthritis Rheum, 43, pp.250~258 (2000)[DOI]
45. Komine M, "Tumor necrosis factor-<TEX>${\alpha}$<", TEX> cooperates with receptor activator of nuclear factor <TEX>${\kappa}B$<, Bone, pp.2001, 28[DOI]
46. Kitaura H, "M-CSF mediates TNF-induced inflammatory osteolysis", J Clin Invest, 115, pp.3418~3427 (2005)[DOI]
47. Azuma Y, "Tumor necrosis factor-<TEX>${\alpha}$<", TEX> induces differentiation of and bone resorption by osteoclasts, 2000, pp.275, 4858~4864
48. Lubberts E, "IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of <TEX>$NF-{\kappa}B$<", TEX> ligand, J Immunol, pp.2003, 170[DOI]
49. Yago T, "IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-<TEX>${\alpha}$<", TEX> antibody: a novel mechanism of osteoclastogenesis by IL-17, 2009, pp.108, 947~955
50. Mun SH, "Tumor necrosis factor <TEX>${\alpha}$<", TEX>-induced interleukin-32 is positively regulated via the Syk, JNK$<, pp.TEX> pathway in rheumatoid synovial fibroblasts, Arthritis Rheum[DOI]
51. Mabilleau G, "Interleukin-32 promotes osteoclast differentiation but not osteoclast activation", PLoS One, 4, pp.e4173~ (2009)[DOI]
52. Boyle WJ, "Osteoclast differentiation and activation", Nature, 423, pp.337~342 (2003)[DOI]
53. Kim YG, "The influence of interleukin-<TEX>$32{\gamma}$<", TEX> on osteoclastogenesis with a focus on fusion-related genes, 2012, pp.32, 201~206
54. Sieper J, "Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes", Arthritis Rheum, 58, pp.649~656 (2008)[DOI]
55. Schett G, "Can we stop progression of ankylosing spondylitis?", Best Pract Res Clin Rheumatol, 24, pp.363~371 (2010)[DOI]
56. Matsuo K, "Osteoclast-osteoblast communication", Arch Biochem Biophys, 473, pp.201~209 (2008)[DOI]
57. Moon YM, "IL-32 and IL-17 interact and have the potential to aggravate osteoclastogenesis in rheumatoid arthritis", Arthritis Res Ther, 14, pp.R246~ (2012)[DOI]
58. Kundu M, "IL-32: an emerging player in the immune response network against tuberculosis?", PLoS Med, 3, pp.e274~ (2006)[DOI]
59. Yucong Z, "Serum functional dickkopf-1 levels are inversely correlated with radiographic severity of ankylosing spondylitis", Clin Lab, 60, pp.1527~1531 (2014)
60. Uderhardt S, "Blockade of dickkopf (DKK)-1 induces fusion of sacroiliac joints", Ann Rheum Dis, 69, pp.592~597 (2010)[DOI]

관련 논문AI추천